PT1014993E - Nova utilizacao de budenosido e formoterol - Google Patents

Nova utilizacao de budenosido e formoterol

Info

Publication number
PT1014993E
PT1014993E PT98944373T PT98944373T PT1014993E PT 1014993 E PT1014993 E PT 1014993E PT 98944373 T PT98944373 T PT 98944373T PT 98944373 T PT98944373 T PT 98944373T PT 1014993 E PT1014993 E PT 1014993E
Authority
PT
Portugal
Prior art keywords
formoterol
budenoside
new use
new
budesonide
Prior art date
Application number
PT98944373T
Other languages
English (en)
Portuguese (pt)
Inventor
Carl-Axel Bauer
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1014993(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1014993E publication Critical patent/PT1014993E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT98944373T 1997-09-19 1998-09-09 Nova utilizacao de budenosido e formoterol PT1014993E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
PT1014993E true PT1014993E (pt) 2002-12-31

Family

ID=20408325

Family Applications (2)

Application Number Title Priority Date Filing Date
PT98944373T PT1014993E (pt) 1997-09-19 1998-09-09 Nova utilizacao de budenosido e formoterol
PT02001670T PT1210943E (pt) 1997-09-19 1998-09-09 Nova utilizacao para budesonida e formoterol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT02001670T PT1210943E (pt) 1997-09-19 1998-09-09 Nova utilizacao para budesonida e formoterol

Country Status (38)

Country Link
US (2) US7897646B2 (enExample)
EP (2) EP1210943B1 (enExample)
JP (1) JP2001517630A (enExample)
KR (1) KR20010024140A (enExample)
CN (1) CN1149998C (enExample)
AR (1) AR013506A1 (enExample)
AT (2) ATE222106T1 (enExample)
AU (1) AU757235B2 (enExample)
BR (1) BR9812325A (enExample)
CA (1) CA2302700C (enExample)
CY (1) CY1106156T1 (enExample)
CZ (1) CZ295250B6 (enExample)
DE (2) DE69807239T2 (enExample)
DK (2) DK1014993T3 (enExample)
EE (1) EE04297B1 (enExample)
ES (2) ES2266322T3 (enExample)
HK (1) HK1045812B (enExample)
HU (1) HUP0003848A2 (enExample)
ID (1) ID24838A (enExample)
IL (1) IL134773A (enExample)
IN (1) IN190791B (enExample)
IS (1) IS2715B (enExample)
MX (1) MXPA00002615A (enExample)
MY (1) MY127812A (enExample)
NO (1) NO327176B1 (enExample)
NZ (1) NZ503173A (enExample)
PL (1) PL190782B1 (enExample)
PT (2) PT1014993E (enExample)
RU (1) RU2199322C2 (enExample)
SA (1) SA98190773B1 (enExample)
SE (1) SE9703407D0 (enExample)
SI (2) SI1210943T1 (enExample)
SK (1) SK285330B6 (enExample)
TR (1) TR200000726T2 (enExample)
TW (1) TW546140B (enExample)
UA (1) UA72446C2 (enExample)
WO (1) WO1999015182A1 (enExample)
ZA (1) ZA988516B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
BR0207062A (pt) * 2001-02-06 2004-10-05 Innovata Biomed Ltd Composição farmacêutica bimodal, inalador para pó seco, método de aplicação de uma quantidade terapeuticamente eficaz de um ingrediente ativo substancialmente fino aos pulmões de um paciente, método de tratamento de um distúrbio respiratório, método de tratamento de doença pulmonar obstrutiva crÈnica (copd), uso de um agente antiinflamatório, uso de um broncodilatador, uso de uma mistura de um agente antiinflamatório e de um broncodilatador, e, processo para a fabricação de uma composição farmacêutica bimodal
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
MX2009004198A (es) * 2006-10-17 2009-10-19 Lithera Inc Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea.
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
GB2477030A (en) * 2010-01-15 2011-07-20 Lithera Inc Lyophilised forms of fluticasone, salmeterol and combinations thereof
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651678B1 (fr) 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP0613371B1 (en) 1991-12-18 2002-03-06 AstraZeneca AB New combination of formoterol and budesonide
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
EA002124B1 (ru) * 1995-11-24 2001-12-24 Смитклайн Бичам С.П.А. Производные хинолина
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP1009408A1 (en) 1997-06-27 2000-06-21 Astra Aktiebolag New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
TW546140B (en) 2003-08-11
ZA988516B (en) 1999-03-19
RU2199322C2 (ru) 2003-02-27
AR013506A1 (es) 2000-12-27
AU9192898A (en) 1999-04-12
JP2001517630A (ja) 2001-10-09
DE69807239D1 (de) 2002-09-19
SK3892000A3 (en) 2000-12-11
SI1210943T1 (sl) 2006-10-31
CA2302700C (en) 2010-11-23
CA2302700A1 (en) 1999-04-01
US20110097282A1 (en) 2011-04-28
NZ503173A (en) 2001-08-31
US20020042404A1 (en) 2002-04-11
SE9703407D0 (sv) 1997-09-19
CN1271287A (zh) 2000-10-25
EE04297B1 (et) 2004-06-15
DE69834955T2 (de) 2007-01-25
US7897646B2 (en) 2011-03-01
CY1106156T1 (el) 2011-06-08
CZ295250B6 (cs) 2005-06-15
DK1014993T3 (da) 2002-11-11
DE69807239T2 (de) 2003-04-10
ID24838A (id) 2000-08-24
DK1210943T3 (da) 2006-09-18
IL134773A0 (en) 2001-04-30
CN1149998C (zh) 2004-05-19
AU757235B2 (en) 2003-02-06
ES2266322T3 (es) 2007-03-01
SI1014993T1 (en) 2003-02-28
SA98190773B1 (ar) 2006-10-02
NO327176B1 (no) 2009-05-04
TR200000726T2 (tr) 2000-09-21
DE69834955D1 (de) 2006-07-27
ATE329599T1 (de) 2006-07-15
ES2182357T3 (es) 2003-03-01
MY127812A (en) 2006-12-29
KR20010024140A (ko) 2001-03-26
BR9812325A (pt) 2000-09-05
IS2715B (is) 2011-02-15
EP1210943A1 (en) 2002-06-05
HK1045812B (en) 2006-12-22
MXPA00002615A (es) 2002-04-24
IS5407A (is) 2000-03-15
PL190782B1 (pl) 2006-01-31
US20060189587A9 (en) 2006-08-24
EP1014993A1 (en) 2000-07-05
HK1045812A1 (en) 2002-12-13
IL134773A (en) 2005-03-20
IN190791B (enExample) 2003-08-23
EE200000145A (et) 2001-02-15
PL339295A1 (en) 2000-12-04
ATE222106T1 (de) 2002-08-15
CZ2000950A3 (cs) 2000-06-14
NO20001401L (no) 2000-03-17
EP1210943B1 (en) 2006-06-14
SK285330B6 (sk) 2006-11-03
WO1999015182A1 (en) 1999-04-01
NO20001401D0 (no) 2000-03-17
HUP0003848A2 (hu) 2001-08-28
UA72446C2 (uk) 2005-03-15
PT1210943E (pt) 2006-09-29
EP1014993B1 (en) 2002-08-14
US8461211B2 (en) 2013-06-11

Similar Documents

Publication Publication Date Title
PT1014993E (pt) Nova utilizacao de budenosido e formoterol
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
FI972781L (fi) Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
FI971969L (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
DE69838728D1 (de) Methoden und zusammensetzungen zum wirksameren abfangen von sauerstoff
DE60010662D1 (de) Kombinationen von formoterol und fluticasonpropionat für asthma
EE05661B1 (et) Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks
IL116479A0 (en) Antifungal compositions and bandage for treatment of nails
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
BR9711530A (pt) Combina-Æo de terapia para tratamento de psicoses
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
FI972433A0 (fi) Rantes-peptidi ja fragmentteja sekä tätä sisältäviä tulehduksen hoitoon soveltuvia koostumuksia
DE69527749D1 (de) Kugelförmige Aktivkohle zur Behandlung von Bauchentzündungen
FI971750A0 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69519602D1 (de) Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden
NO952568D0 (no) Behandling av cellulosemateriale og blandinger for anvendelse for dette
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
FI963264A7 (fi) Tromboksaani A2-välitteisten sairauksien ennaltaestoon ja hoitoon tarkoitettu aine
FI944687A7 (fi) Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi